May 2023

OPHTHALMOLOGY

LEVODOPA ASSOCIATED WITH REDUCED RISK OF THE DEVELOPMENT OF NEOVASCULAR AMD, STUDY FINDS

An analysis of levodopa use published in Ophthalmology Retina by Jeremy A. Lavine MD, PhD, of Northwestern Medicine Ophthalmology, showed cumulative two-year exposure to daily doses of levodopa between 100 – 300 mg and > 300 mg were associated with decreased odds of the development of neovascular age-related macular degeneration by 14% and 23%, respectively.
 
“Levodopa use was associated with reduced detection of new-onset neovascular AMD,” says Dr. Lavine. “A prospective, randomized clinical trial should be considered to investigate whether low-dose levodopa reduces neovascular AMD.”
 
Read more about the study >

Refer a Patient

Northwestern Medicine welcomes the opportunity to partner with you in caring for your patients. ​

You May Also Like